Arcturus Therapeutics Reports Q4 2025 Results, Misses Revenue Estimates
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biopharmaceutical company focused on mRNA-based therapeutics for rare diseases, has announced its financial results for the fourth quarter and full fiscal year 2025. The report, which included updates on its clinical pipeline, revealed a significant revenue shortfall against analyst expectations, contributing to a negative after-hours trading reaction.
Earnings and Revenue Versus Estimates
The company's financial performance for the quarter fell notably short of Wall Street forecasts. Arcturus reported collaboration and grant revenue of $7.2 million for Q4 2025, a sharp decline from the $22.8 million reported in the same period last year. This result missed the consensus analyst estimate of $18.0 million by approximately 60%.
On the bottom line, the net loss was slightly better than anticipated. Arcturus posted a net loss of $29.1 million, or a loss of $1.03 per diluted share, compared to a net loss of $30.0 million, or $1.11 per share, in Q4 2024. The reported loss per share was deeper than the analyst estimate of a $0.73 loss.
The key financial comparisons for the quarter are as follows:
- Reported Q4 Revenue: $7.2 million
- Estimated Q4 Revenue: $18.0 million
- Variance: -$10.8 million (Miss)
- Reported Q4 EPS: -$1.03
- Estimated Q4 EPS: -$0.73
- Variance: -$0.30 (Miss)
For the full fiscal year 2025, total revenue was $82.0 million, down from $152.3 million in 2024. The annual net loss improved to $65.8 million ($2.40 per share) from $80.9 million ($3.00 per share) in the prior year.
Market Reaction
The market's immediate response to the earnings release was negative. In after-hours trading following the announcement, Arcturus stock declined approximately 5.2%. This reaction appears primarily driven by the substantial revenue miss, overshadowing the company's progress in reducing its annual net loss and extending its cash runway. Prior to the earnings release, the stock had been relatively flat over the past month.
Pipeline and Corporate Updates
Beyond the financials, the earnings press release highlighted several developments in Arcturus's clinical pipeline:
- Cystic Fibrosis (ARCT-032): The company confirmed it is on track to initiate a new 12-week Phase 2 study for its inhaled mRNA therapy in the first half of 2026. The safety review committee has cleared the program to proceed following the completion of three 28-day dosing cohorts.
- OTC Deficiency (ARCT-810): Arcturus is broadening the development strategy for this liver-targeted mRNA therapeutic to address both adult and severe pediatric populations. Regulatory meetings with health authorities remain scheduled for the first half of 2026.
- Vaccine Programs: The company noted the UK MHRA approval of its sa-mRNA COVID-19 vaccine, KOSTAIVE®, in January 2026. It also reported positive eight-month durability data for its pandemic influenza vaccine candidate under development with BARDA.
- Financial Position: Management emphasized disciplined execution, reporting cash, cash equivalents, and restricted cash of $232.8 million as of December 31, 2025. They stated this position extends the company's cash runway into the second quarter of 2028.
Looking Ahead
The company did not provide specific financial guidance for the coming year in its press release. Analyst estimates for Arcturus project full-year 2026 sales of approximately $82.3 million. For the upcoming first quarter of 2026, the consensus sales estimate stands at $10.8 million, with an expected loss per share of $0.83. Investors will likely focus on the timing and data readouts from the upcoming Phase 2 cystic fibrosis trial and regulatory feedback on the OTC deficiency program as key near-term catalysts.
For a detailed breakdown of historical earnings and future analyst estimates for Arcturus Therapeutics, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.